Suppliers and packagers for generic pharmaceutical drug: BISOPROLOL FUMARATE

BISOPROLOL FUMARATE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Alembic	BISOPROLOL FUMARATE	bisoprolol fumarate	TABLET;ORAL	204891	ANDA	Alembic Pharmaceuticals Limited	46708-603-30	30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (46708-603-30)	2019-09-11
Alembic	BISOPROLOL FUMARATE	bisoprolol fumarate	TABLET;ORAL	204891	ANDA	Alembic Pharmaceuticals Limited	46708-603-31	100 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (46708-603-31)	2019-09-11
Alembic	BISOPROLOL FUMARATE	bisoprolol fumarate	TABLET;ORAL	204891	ANDA	Alembic Pharmaceuticals Limited	46708-603-71	500 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (46708-603-71)	2019-09-11
Alembic	BISOPROLOL FUMARATE	bisoprolol fumarate	TABLET;ORAL	204891	ANDA	Alembic Pharmaceuticals Limited	46708-604-30	30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (46708-604-30)	2019-09-11
Alembic	BISOPROLOL FUMARATE	bisoprolol fumarate	TABLET;ORAL	204891	ANDA	Alembic Pharmaceuticals Limited	46708-604-31	100 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (46708-604-31)	2019-09-11

Bisoprolol Fumarate Pharmaceutical Supply Chain Analysis

Last updated: February 19, 2026

Bisoprolol fumarate, a selective beta-1 adrenergic receptor blocker, is a widely prescribed medication for treating cardiovascular conditions including hypertension and heart failure. The global supply chain for its active pharmaceutical ingredient (API) and key intermediates is characterized by a concentrated manufacturing base, with a significant portion of production located in Asia. The market is influenced by regulatory compliance, quality control standards, and the competitive landscape of generic drug manufacturing.

Who are the Primary API Suppliers for Bisoprolol Fumarate?

The production of bisoprolol fumarate API is concentrated among a limited number of manufacturers, primarily located in India and China. These suppliers are critical to the global availability of the drug.

• Key API Manufacturing Regions: India and China dominate API production for bisoprolol fumarate.
• Leading Manufacturers: Specific companies are identified through patent filings, regulatory approvals, and industry reports. While direct naming of current market leaders can fluctuate based on commercial agreements and regulatory status, historical and publicly available information points to entities with established Good Manufacturing Practice (GMP) certifications and a history of supplying to regulated markets.
• Quality and Regulatory Compliance: Suppliers must adhere to stringent international quality standards, including those set by the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and other national regulatory bodies. This involves rigorous quality control processes, impurity profiling, and stability testing.

Table 1: General Characteristics of Bisoprolol Fumarate API Suppliers

Characteristic	Description
Geographic Focus	Predominantly India and China.
Regulatory Status	Must possess GMP certifications and often have Drug Master Files (DMFs) or Certificates of Suitability (CEPs) filed with regulatory authorities.
Production Scale	Capable of large-scale, consistent production to meet global demand.
Quality Assurance	Robust quality management systems, validated manufacturing processes, and comprehensive analytical testing.
Cost Structure	Competitive pricing influenced by economies of scale and regional manufacturing costs.

What are the Key Intermediates in Bisoprolol Fumarate Synthesis?

The synthesis of bisoprolol fumarate involves several key chemical intermediates. The reliable supply and quality of these intermediates are foundational to the final API production.

• Core Chemical Pathway: The synthesis typically involves reacting a substituted phenoxypropanolamine derivative with 1-(isopropylamino)-3-phenoxypropan-2-ol.
• Key Intermediate 1: 4-(2-Isopropoxyethoxy)phenol: This is a crucial starting material. Variations in its purity or synthesis can impact the final product.
• Key Intermediate 2: 3-Chloro-1-(4-(2-isopropoxyethoxy)phenoxy)propan-2-ol: This intermediate is formed through further chemical steps, often involving epichlorohydrin.
• Other Reagents: Isopropylamine is a critical reagent used in the final amination step.
• Supplier Landscape for Intermediates: The market for these intermediates is also global, with manufacturers often specializing in specific chemical synthesis steps. Some API manufacturers may produce intermediates in-house, while others source them from third-party chemical suppliers.

Table 2: Primary Intermediates in Bisoprolol Fumarate Synthesis

Intermediate Name	Role in Synthesis
4-(2-Isopropoxyethoxy)phenol	Core aromatic starting material.
Epichlorohydrin	Used to form the epoxide or chlorohydrin linkage.
3-Chloro-1-(4-(2-isopropoxyethoxy)phenoxy)propan-2-ol	Precursor to the final amine formation.
Isopropylamine	Reacts to form the secondary amine group of bisoprolol.
Fumaric Acid	Used for salt formation to produce bisoprolol fumarate.

What are the Regulatory Requirements for API and Intermediate Suppliers?

Suppliers must meet stringent regulatory standards to ensure the safety, efficacy, and quality of bisoprolol fumarate.

• Good Manufacturing Practices (GMP): All manufacturing facilities must comply with GMP guidelines relevant to the target markets (e.g., ICH Q7 for APIs). This covers facility design, equipment validation, personnel training, process controls, and documentation.
• Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies like the FDA. A DMF contains confidential, detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs.
• Certificates of Suitability (CEPs): In Europe, CEPs issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM) demonstrate that an API complies with the European Pharmacopoeia monograph.
• Impurity Profiling and Control: Regulatory agencies require thorough identification, quantification, and control of process-related impurities and degradation products. Specific impurity limits are defined in pharmacopoeial monographs.
• Audits and Inspections: Facilities are subject to routine inspections by regulatory authorities and customer audits to ensure ongoing compliance.

What is the Competitive Landscape for Bisoprolol Fumarate API Production?

The market for bisoprolol fumarate API is characterized by a competitive environment, driven by generic drug manufacturers seeking cost-effective and reliable sources.

• Generic Market Dominance: Bisoprolol fumarate is widely available as a generic medication, leading to price sensitivity among finished dosage form manufacturers.
• Consolidation and Capacity: While numerous players may exist, actual large-scale, regulated API production capacity is concentrated. Suppliers with robust regulatory dossiers and a proven track record often hold a significant market share.
• Intellectual Property: While the primary composition of matter patents for bisoprolol have long expired, process patents and polymorph patents can still influence manufacturing strategies and market entry for new suppliers.
• Supply Chain Resilience: Pharmaceutical companies increasingly scrutinize supply chain resilience, seeking multiple qualified suppliers to mitigate risks associated with geopolitical events, natural disasters, or manufacturing disruptions.

Table 3: Factors Influencing Bisoprolol Fumarate API Competition

Factor	Impact on Competition
API Cost	Direct impact on the profitability of generic finished dosage forms.
Regulatory Approvals	Ability to supply to regulated markets (US, EU, Japan) is a key differentiator.
Quality and Consistency	Consistent batch-to-batch quality is essential for pharmaceutical formulations.
Supply Chain Reliability	Consistent and timely delivery is critical for finished drug production schedules.
Intellectual Property	Limited impact on the core API market due to patent expiry, but process innovations can emerge.
Manufacturing Capacity	Ability to scale production to meet global demand.

What are the Potential Risks in the Bisoprolol Fumarate Supply Chain?

Several risks can impact the continuity and quality of bisoprolol fumarate supply.

• Regulatory Non-Compliance: A single instance of GMP violation or product recall can lead to significant supply disruptions and reputational damage for a supplier. Regulatory agencies have increased scrutiny on API manufacturers.
• Geopolitical Instability: Concentration of manufacturing in specific regions makes the supply chain vulnerable to political tensions, trade disputes, or regional conflicts that could disrupt production or export.
• Raw Material Sourcing: Reliance on a limited number of intermediate or raw material suppliers can create upstream vulnerabilities.
• Quality Control Failures: Inadequate impurity control or batch failures can lead to costly rejections, production delays, and potential patient safety issues.
• Natural Disasters and Pandemics: As demonstrated by recent global events, these can impact manufacturing operations, logistics, and personnel availability.
• Intellectual Property Disputes: While less common for established generics, disputes over novel synthesis routes or polymorphs could arise, impacting specific suppliers.

What Due Diligence is Necessary for Selecting Suppliers?

Thorough due diligence is paramount for pharmaceutical companies sourcing bisoprolol fumarate API and critical intermediates.

• Regulatory Audit: Conduct comprehensive on-site audits of manufacturing facilities to verify GMP compliance, quality systems, and operational controls.
• DMF/CEP Review: Thoroughly review filed DMFs or CEPs for completeness and regulatory acceptance in target markets.
• Quality Agreements: Establish robust quality agreements outlining responsibilities for quality control, change management, deviation handling, and complaint investigations.
• Financial Stability Assessment: Evaluate the financial health and stability of potential suppliers to ensure long-term viability.
• Supply Chain Mapping: Understand the supplier's upstream supply chain for key raw materials and intermediates to identify potential bottlenecks.
• Business Continuity Planning: Assess the supplier's preparedness for potential disruptions, including disaster recovery and contingency plans.
• Performance History: Review the supplier's historical performance, including on-time delivery rates, quality metrics, and regulatory compliance history.

Key Takeaways

The bisoprolol fumarate API supply chain is largely concentrated in India and China, with manufacturers facing stringent regulatory oversight. Key intermediates are critical to API quality, and their sourcing requires similar due diligence. Competition is driven by cost and regulatory adherence, making robust quality management and supply chain resilience essential for reliable access to this vital cardiovascular medication.

---

Frequently Asked Questions

What is the typical lead time for a new bisoprolol fumarate API supplier to become qualified?

The qualification process for a new bisoprolol fumarate API supplier can range from six months to over two years. This timeline encompasses initial supplier assessment, comprehensive quality and regulatory audits, batch sampling and testing, and potential validation batches. The duration is significantly influenced by the supplier's existing regulatory status, the complexity of their quality systems, and the thoroughness of the pharmaceutical company's internal qualification procedures.

Are there specific impurity profiles that regulatory agencies scrutinize more closely for bisoprolol fumarate?

Yes, regulatory agencies like the FDA and EMA scrutinize impurity profiles based on pharmacopoeial standards and ICH guidelines. For bisoprolol fumarate, attention is often paid to process-related impurities originating from starting materials or by-products of the synthesis, such as unreacted intermediates or isomers. Degradation products that may form during storage are also critical. Suppliers must demonstrate robust control strategies to keep these impurities below specified limits, often detailed in the API's DMF or CEP.

How does the fumarate salt form impact the API supply chain compared to a free base?

The fumarate salt form specifically requires an additional step in the API manufacturing process: the reaction of bisoprolol free base with fumaric acid to form the salt. This requires sourcing high-purity fumaric acid and ensuring proper salt crystallization and drying processes. The salt form influences the API's physical properties, such as solubility, stability, and polymorphism, which can also be subjects of regulatory review. Suppliers must demonstrate consistent control over these salt formation and crystallization parameters.

What are the primary risks associated with a single-source supplier for bisoprolol fumarate API?

A single-source supplier for bisoprolol fumarate API presents significant risks including supply disruption due to the supplier's manufacturing issues, quality failures, regulatory actions, or even business insolvency. This can lead to drug shortages, impacting patient access to essential medication. It also limits negotiation leverage and can expose the pharmaceutical company to price increases or less favorable commercial terms.

How do patent expirations for bisoprolol fumarate affect the supplier landscape and pricing?

The patent expiration for the composition of matter for bisoprolol fumarate has led to a highly competitive generic market. This allows multiple API manufacturers to enter and produce the drug, increasing supply and driving down prices. While process patents or polymorph patents can still exist and influence specific manufacturing routes, the overall landscape is characterized by price competition among established API suppliers who can meet stringent quality and regulatory requirements.

---

Citations

[1] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2000). ICH Harmonised Tripartite Guideline Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients.